BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23176615)

  • 1. Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways.
    Frampton AE; Krell J; Giovannetti E; Krell D; Stebbing J; Castellano L; Jiao LR
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1275-8. PubMed ID: 23176615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN.
    Xiong J; Wang D; Wei A; Lu H; Tan C; Li A; Tang J; Wang Y; He S; Liu X; Hu W
    Exp Cell Res; 2017 Dec; 361(2):316-323. PubMed ID: 29111166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative survival-based molecular profiling of human pancreatic cancer.
    Donahue TR; Tran LM; Hill R; Li Y; Kovochich A; Calvopina JH; Patel SG; Wu N; Hindoyan A; Farrell JJ; Li X; Dawson DW; Wu H
    Clin Cancer Res; 2012 Mar; 18(5):1352-63. PubMed ID: 22261810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway.
    Liu X; Tan X; Liu P; Wu Y; Qian S; Zhang X
    Oncol Res; 2018 Aug; 26(7):1123-1131. PubMed ID: 29386088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of miR-184 on Proliferation and Apoptosis of Pancreatic Ductal Adenocarcinoma and Its Mechanism.
    Li S; Li H; Ge W; Song K; Yuan C; Yin R
    Technol Cancer Res Treat; 2020; 19():1533033820943237. PubMed ID: 32914707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.
    Zhang H; Pan YZ; Cheung M; Cao M; Yu C; Chen L; Zhan L; He ZW; Sun CY
    Cell Death Dis; 2019 Mar; 10(3):230. PubMed ID: 30850586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
    Mohammed A; Qian L; Janakiram NB; Lightfoot S; Steele VE; Rao CV
    Int J Cancer; 2012 Oct; 131(8):1951-62. PubMed ID: 22287227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PKCι Is a Promising Prognosis Biomarker and Therapeutic Target for Pancreatic Cancer.
    Abdelatty A; Fang D; Wei G; Wu F; Zhang C; Xu H; Yao C; Wang Y; Xia H
    Pathobiology; 2022; 89(6):370-381. PubMed ID: 35785767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
    Xie P; Tan SY; Li HF; Tang HD; Zhou JH
    J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
    You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
    Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
    Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
    J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma.
    Duan J; Li X; Huang S; Zeng Y; He Y; Liu H; Lin D; Lu D; Zheng M
    Mol Med Rep; 2018 Mar; 17(3):4187-4194. PubMed ID: 29344673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma.
    Li W; Chen C; Zhao X; Ye H; Zhao Y; Fu Z; Pan W; Zheng S; Wei L; Nong T; Li Z; Chen R
    J Cell Mol Med; 2017 Nov; 21(11):2896-2908. PubMed ID: 28544376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway.
    Wang L; Zhang B; Zheng W; Kang M; Chen Q; Qin W; Li C; Zhang Y; Shao Y; Wu Y
    Sci Rep; 2017 Jul; 7(1):5384. PubMed ID: 28710412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.